Effect of antidepressant and antimanic drugs on amine uptake in man. 1974

W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D007488 Iprindole A tricyclic antidepressant that has actions and uses similar to those of AMITRIPTYLINE, but has only weak antimuscarinic and sedative effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p257)
D008094 Lithium An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. Lithium-7,Lithium 7
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive

Related Publications

W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
May 1994, Nihon rinsho. Japanese journal of clinical medicine,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
April 1976, British journal of clinical pharmacology,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
June 1982, The Journal of pharmacy and pharmacology,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
September 1965, Journal of psychosomatic research,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
October 1975, Biochemical pharmacology,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
March 1981, Journal of neurochemistry,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
January 1983, Arzneimittel-Forschung,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
August 1976, Canadian journal of physiology and pharmacology,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
May 1972, The New England journal of medicine,
W E Fann, and J M Davis, and D S Janowsky, and J S Kaufmann, and J H Cavanaugh, and J A Oates
January 2007, Neuroscience and biobehavioral reviews,
Copied contents to your clipboard!